Penn Medicine Provider
Renal Electrolyte and Hypertension
Gaia Coppock, MD
5.0
(361)
Accepting new patients
Sees patients age 18 and up
Penn Renal Electrolyte and Hypertension Perelman
View 1 additional location

About me

  • Assistant Professor of Clinical Medicine (Renal-Electrolyte and Hypertension)

Education and training

  • Medical School: University of Texas
  • Residency: University of Virginia Health System
  • Fellowship: Hospital of the University of Pennsylvania

What my patients think about me

Average Rating
5.0

362 reviews

Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.

May 2025
5.0
5.0
great doctor
April 2025
5.0
5.0
the best
April 2025
5.0
5.0
excellent provider
April 2025
5.0
5.0
she is just excellent in every respect.

Insurance accepted

My Locations

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
  • Penn Presbyterian Medical Center: Has privileges to treat patients in the hospital.
Dr. Coppock is a Penn Medicine physician.

Qualifications and experience

Treatments and Conditions

My research

Dorota Marchel, Howard Trachtman, Maria Larkina, Margaret Helmuth, Jennifer Y Lai Yee, Damian Fermin, Andrew S Bomback, Pietro A Canetta, Debbie S Gipson, Amy K Mottl, Rulan S Parekh, Manish K Saha, Matthew G Sampson, Richard A Lafayette, Laura H Mariani The Significance of Hematuria in Podocytopathies , Clin J Am Soc Nephrol, 19((1):56-66): 2024,56-66


Chia-Shi Wang, Dorey A Glenn, Margaret Helmuth, Abigail R Smith, Andrew S Bomback, Pietro A Canetta, Gaia M Coppock, Myda Khalid, Katherine R Tuttle, Raed Bou-Matar, Larry A Greenbaum, Bruce M Robinson, Lawrence B Holzman, William E Smoyer, Michelle N Rheault, Debbie Gipson, Laura H Mariani; Cure Glomerulonephropathy (CureGN) Study Consortium Association of COVID-19 Versus COVID-19 Vaccination With Kidney Function and Disease Activity in Primary Glomerular Disease: A Report of the Cure Glomerulonephropathy Study , Am J Kidney Dis, 83((1):37-46): 2024


Brad H Rovin, Jonathan Barratt, Hiddo J L Heerspink, Charles E Alpers, Stewart Bieler, Dong-Wan Chae, Ulysses A Diva, Jürgen Floege, Loreto Gesualdo, Jula K Inrig, Donald E Kohan, Radko Komers, Laura Ann Kooienga, Richard Lafayette, Bart Maes, Robert Małecki, Alex Mercer, Irene L Noronha, Se Won Oh, Chen Au Peh, Manuel Praga, Priscila Preciado, Jai Radhakrishnan, Michelle N Rheault, William E Rote, Sydney C W Tang, Vladimir Tesar, Howard Trachtman, Hernán Trimarchi, James A Tumlin, Muh Geot Wong, Vlado Perkovic; DUPRO steering committee and PROTECT Investigators Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial , Lancet, 402((10417):2077-2090): 2023,2077-2090


Michelle N Rheault, Charles E Alpers, Jonathan Barratt, Stewart Bieler, Pietro Canetta, Dong-Wan Chae, Gaia Coppock, Ulysses Diva, Loreto Gesualdo, Hiddo J L Heerspink, Jula K Inrig, Gianna M Kirsztajn, Donald Kohan, Radko Komers, Laura A Kooienga, Kenneth Lieberman, Alex Mercer, Irene L Noronha, Vlado Perkovic, Jai Radhakrishnan, William Rote, Brad Rovin, Vladimir Tesar, Hernán Trimarchi, James Tumlin, Muh Geot Wong, Howard Trachtman; DUPRO Steering Committee and DUPLEX Investigators Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis , N Engl J Med, 389(26): 2023,2436-2445


Mottl AK, Bomback AS, Mariani LH, Coppock G, Jennette JC, Almaani S, Gipson DS, Kelley S, Kidd J, Laurin LP, Mucha K, Oliverio A, Palmer M, Rizk D, Sanghani N, Stokes MB, Susztak K, Wadhwani S, Nast CC. CureGN-Diabetes Study: Rationale, Design, and Methods of a Prospective Observational Study of Glomerular Disease Patients with Diabetes , Glomerular Dis, 3: 2023,155-164


Heerspink HJL, Radhakrishnan J, Alpers CE, Barratt J, Bieler S, Diva U, Inrig J, Komers R, Mercer A, Noronha IL, Rheault MN, Rote W, Rovin B, Trachtman H, Trimarchi H, Wong MG, Perkovic V; PROTECT Investigators. Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial , Lancet, 401(13;401): 2023,1584-1594


Laura H Mariani, Sean Eddy, Fadhl M AlAkwaa, Phillip J McCown, Jennifer L Harder, Viji Nair, Felix Eichinger, Sebastian Martini, Adebowale D Ademola, Vincent Boima, Heather N Reich, Jamal El Saghir, Bradley Godfrey, Wenjun Ju, Emily C Tanner, Virginia Vega-Warner, Noel L Wys, Sharon G Adler, Gerald B Appel, Ambarish Athavale, Meredith A Atkinson, Serena M Bagnasco, Laura Barisoni, Elizabeth Brown, Daniel C Cattran, Gaia M Coppock, Katherine M Dell, Vimal K Derebail, Fernando C Fervenza, Alessia Fornoni, Crystal A Gadegbeku, Keisha L Gibson, Laurence A Greenbaum, Sangeeta R Hingorani, Michelle A Hladunewich, Jeffrey B Hodgin, Marie C Hogan, Lawrence B Holzman, J Ashley Jefferson, Frederick J Kaskel, Jeffrey B Kopp, Richard A Lafayette, Kevin V Lemley, John C Lieske, Jen-Jar Lin, Rajarasee Menon, Kevin E Meyers, Patrick H Nachman, Cynthia C Nast, Michelle M O'Shaughnessy, Edgar A Otto, Kimberly J Reidy, Kamalanathan K Sambandam, John R Sedor, Christine B Sethna, Pamela Singer, Tarak Srivastava, Cheryl L Tran, Katherine R Tuttle, Suzanne M Vento, Chia-Shi Wang, Akinlolu O Ojo, Dwomoa Adu, Debbie S Gipson, Howard Trachtman, Matthias Kretzler Precision nephrology identified tumor necrosis factor activation variability in minimal change disease and focal segmental glomerulosclerosis , Kidney Int, 103((3);565-579): 2023


Dhruti P Chen 1, Margaret E Helmuth 2, Abigail R Smith 2, Pietro A Canetta 3, Isabelle Ayoub 4, Krzysztof Mucha 5, Mahmoud Kallash 6, Jeffrey B Kopp 7, Rasheed Gbadegesin 8, Brenda W Gillespie 2, Larry A Greenbaum 9, Rulan S Parekh 10, Tracy E Hunley 11, C John Sperati 12, David T Selewski 13, Jason Kidd 14, Aftab Chishti 15, Kimberly Reidy 3, Amy K Mottl 8, Debbie S Gipson 2, Tarak Srivastava 16, Katherine E Twombley 13; CureGN Consortium Age of Onset and Disease Course in Biopsy-Proven Minimal Change Disease: An Analysis From the Cure Glomerulonephropathy Network , Am J Kidney Dis, 81((2):695-706.e1): 2023


Gupta S, Strohbehn IA, Wang Q, Hanna PE, Seethapathy R, Prosek JM, Herrmann SM, Abudayyeh A, Malik AB, Loew S, Carlos CA, Chang WT, Beckerman P, Mithani Z, Shah CV, Renaghan AD, de Seigneux S, Campedel L, Kitchlu A, Shin DS, Coppock G, Lumlertgul N, Garcia P, Ortiz-Melo DI, Rashidi A, Sprangers B, Aggarwal V, Benesova K, Jhaveri KD, Cortazar FB, Weins A, Zuo Y, Mooradian MJ, Reynolds KL, Leaf DE, Sise ME; ICPi-AKI Consortium. Acute kidney injury in patients receiving pembrolizumab combination therapy versus pembrolizumab monotherapy for advanced lung cancer , Kidney Int, 102(4): 2022,930-935


Gupta S, Garcia-Carro C, Prosek JM, Glezerman I, Herrmann SM, Garcia P, Abudayyeh A, Lumlertgul N, Malik AB, Loew S, Beckerman P, Renaghan AD, Carlos CA, Rashidi A, Mithani Z, Deshpande P, Rangarajan S, Shah CV, Seigneux S, Campedel L, Kitchlu A, Shin DS, Coppock G, Ortiz-Melo DI, Sprangers B, Aggarwal V, Benesova K, Wanchoo R, Murakami N, Cortazar FB, Reynolds KL, Sise ME, Soler MJ, Leaf DE; ICPi-AKI Consortium Investigators. Shorter versus longer corticosteroid duration and recurrent immune checkpoint inhibitor-associated AKI , J Immunother Cancer, 10(9): 2022,e005646